New hope for hepatitis d: experimental drug RBD1016 enters Mid-Stage trial
NCT ID NCT06649266
First seen Feb 03, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study tests whether the drug RBD1016 can safely lower the amount of hepatitis D virus in adults with chronic infection. Fourteen participants will receive either RBD1016 or a placebo over several visits. The main goal is to see if the drug reduces viral levels and to check for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS D are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Infektionskliniken, Danderyds sjukhus
Stockholm, 18288, Sweden
-
Medicinsk enhet för Infektionssjukdomar, Karolinska Universitetssjukhuset Huddinge
Stockholm, 14186, Sweden
Conditions
Explore the condition pages connected to this study.